Xinkai

Xinkai Company was established in 1994 in Illinois, USA, with its headquarters in Chicago, USA. Backed by the Rush Medical Center of the University of Chicago, the company is dedicated to improving human health, researching and developing new drugs, and promoting advanced international medical technologies. Xinkai integrates new drug research and development, production, and sales, primarily committed to providing comprehensive and all-round disease treatment solutions to domestic and international patients with immune connective tissue diseases and hyperimmune function. While focusing on new drug development, Xinkai also emphasizes new drug marketing and sales, establishing a unique, professional academic promotion approach targeting departments such as Rheumatology and Immunology, Nephrology and Urology, and Hepatology and Surgery. It also utilizes the latest network technologies to build a doctor-patient communication platform, serving doctors and patients, thereby contributing to harmonious doctor-patient relationships. To date, Xinkai has established a marketing network covering all of China that integrates development, sales, and promotion, and has assembled a professional market and sales team of over 200 people. Xinkai is committed to building strategic partnerships with commercial partners that share benefits, providing high-level academic support and services to hospitals and doctors, and offering health services and a health consultation platform to patients.